Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Commercial Officer, MRD | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 389,350 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 6,444 · Balance 389,350 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 22:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,444 | $30.00 | $193,320.00 |
DisclosureSEC source: 0001820885-26-000025 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,350 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 22:50 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,195 | $27.00 | $32,265.00 |
DisclosureSEC source: 0001820885-26-000023 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 395,794 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 23:33 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001820885-26-000020 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 396,989 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 22:26 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,299 | $24.00 | $31,176.00 |
DisclosureSEC source: 0001820885-26-000018 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,989 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,000 | $23.00 | $115,000.00 |
DisclosureSEC source: 0001820885-26-000016 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 401,288 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 487 | $22.00 | $10,714.00 |
DisclosureSEC source: 0001820885-26-000014 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 406,288 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 23:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,000 | $20.50 | $102,500.00 |
DisclosureSEC source: 0001820885-26-000012 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 406,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 23:13 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,000 | $19.00 | $95,000.00 |
DisclosureSEC source: 0001820885-26-000010 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 411,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,000 | $18.00 | $198,000.00 |
DisclosureSEC source: 0001820885-26-000008 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 41,338 | $13.17 | $544,421.46 |
DisclosureSEC source: 0001820885-26-000004 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,775 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:31 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001820885-26-000002 · form4.xml · nonDerivative · entry 2 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,113 Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:31 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 59,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001820885-26-000002 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,613 Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:22 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 26,023 | $6.98 | $181,640.54 |
DisclosureSEC source: 0001062993-25-004817 · form4.xml · nonDerivative · entry 2 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,238 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:22 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 180,029 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001062993-25-004817 · form4.xml · derivative · entry 3 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,029 Underlying: Common Stock · 180,029 shares Expires 2035-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:22 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 119,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004817 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,261 Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:47 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001062993-24-017564 · form4.xml · derivative · entry 2 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are fully exercisable. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:47 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,000 | $1.98 | $9,900.00 |
DisclosureSEC source: 0001062993-24-017564 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,975 | $3.44 | $23,994.00 |
DisclosureSEC source: 0001062993-24-005757 · form4.xml · nonDerivative · entry 3 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,290 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,016 | $3.43 | $20,634.88 |
DisclosureSEC source: 0001062993-24-005757 · form4.xml · nonDerivative · entry 2 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,265 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 199,549 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001062993-24-005757 · form4.xml · derivative · entry 4 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,549 Underlying: Common Stock · 199,549 shares Expires 2034-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 132,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005757 · form4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,281 Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 22,894 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-21-018737 · doc4.xml · derivative · entry 2 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,894 Underlying: Common Stock · 22,894 shares Expires 2021-03-04 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 9,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018737 · doc4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-20-063101 · doc4.xml · derivative · entry 3 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 25,000 shares Expires 2024-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. F2 · derivative.exercise_date: All options are fully exercisable. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 25,000 | $55.00 | $1,375,000.00 |
DisclosureSEC source: 0001209191-20-063101 · doc4.xml · nonDerivative · entry 2 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 25,000 | $1.98 | $49,500.00 |
DisclosureSEC source: 0001209191-20-063101 · doc4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-20-052780 · doc4.xml · derivative · entry 3 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 10,000 shares Expires 2024-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. F2 · derivative.exercise_date: All options are fully exercisable. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $50.00 | $500,000.00 |
DisclosureSEC source: 0001209191-20-052780 · doc4.xml · nonDerivative · entry 2 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $1.98 | $19,800.00 |
DisclosureSEC source: 0001209191-20-052780 · doc4.xml · nonDerivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. Read SEC document |
| August 13, 2020 Filed Aug 15, 2020 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $39.50 | $0.00 |
DisclosureSEC source: 0001209191-20-046870 · doc4.xml · derivative · entry 1 BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-08-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on August 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.